期刊文献+

膀胱癌患者术后不同剂量卡介苗腔内灌注所产生的免疫效果及副作用比较 被引量:2

Immunization & Side Effect Comparison of BCG Intracavitary Perfusion at Different Dose for Patients with Bladder Carcinoma After Surgery
原文传递
导出
摘要 目的比较膀胱癌患者术后不同剂量卡介苗腔内灌注所产生的免疫效果及副作用。方法将入选病例随机分为2组,术后分别灌注卡介苗60、120mg,用流式细胞仪检测灌注前、后外周血T细胞亚群的变化,作为评价免疫效果的指标;同时比较2组的副作用发生情况。结果与灌注前比较,灌注后CD4因子2组均明显升高(P<0.05),灌注后CD8因子2组均明显降低(P<0.05);灌注后2组间比较,无显著性差异(P>0.05)。60mg组副作用发生率及程度明显低于120mg组。结论小剂量卡介苗灌注可取得与大剂量相近的免疫效果,副作用低。 OBJECTIVE: To compare the immune effect and side effect of BCG intracavitary instillation at different dose for patients with bladder carcinoma after the surgery.METHODS: The patients were divided into two groups randomly and treated with BCG intracavitary instillation after surgery.The dose was 60mg and 120mg, respectively.The peripheral blood T lymphocyte subsets were tested as the index of immune effect evaluation with flow cytometry before and after instillation.The side effects of the two groups were also compared. RESULTS:The level of CD4 factor statistically increased after instillation in both groups ( P 〈 0.05) ; CD8 obviously decreased ( P 〈 0.05). There was no statistical difference between two groups ( P 〉 0.05) ; the incidence and degree of side effects was obviously lower in group of 60mg than in group of 120mg.CONCLUSION: The similar immune effects and lower side effects were obtained with. low dose BCG intracavitary instillation compared with the large dose.
出处 《中国药房》 CAS CSCD 北大核心 2007年第5期360-361,共2页 China Pharmacy
关键词 膀胱癌 卡介苗 免疫效果 副作用 Bladder carcinoma BCG Immunization Side effect
  • 相关文献

参考文献6

  • 1兰卫华,靳风烁,王洛夫,谢芳,王晶.卡介苗与丝裂霉素C膀胱灌注预防浅表性膀胱癌复发疗效及毒性比较的Meta分析[J].中华泌尿外科杂志,2006,27(1):29-32. 被引量:36
  • 2Stephen P,Andrew M ,Jackson SJ, et al .Mechanism of action of intraresical Bacille Calmette- Guerin(BCG) :local immune mechanisms[J ]. Clinical Infectious Disease, 2000,31(2) : 91.
  • 3Schmidt AC, Bouic P J, Hegns CF, et al .Peripheral blood lymphocyte response in patients with superficial transitional cell carconome of the bladder treated with BCG- A useful marker of response[J].British J Urol, 1993,71(2) : 179.
  • 4Keyes E, Carballido J, Anzano LM, et al .The association between CD2 peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG - patients[J ] .British J Cancer, 1999,79(7): 1 162.
  • 5Paganno F, Bassi P, Milani C, et al .A low dose BCG regime in superficial cancer therpy is it effective? [J ] .J Urol, 1991,146(1) :32.
  • 6Alvako M, Curtis J, Jams W, et al .Dose response of BCG in the treatment of superficial bladder cancer[J ].J Urol, 1992,147(5) : 596.

二级参考文献17

  • 1戴宇平,郑克立,曾金云,陈立中.丝裂霉素与卡介苗膀胱灌注预防浅表膀胱癌复发的比较[J].新医学,1996,27(10):513-514. 被引量:8
  • 2Pagano F,Guazzieri S,Garbeglio A,et al.Mitomycin C,adriamycin and bacillus of Calmette-Guerin as adjuvant topical therapy in superficial transitional cell carcinoma.Acta Urol Ital,1987,1 (Suppl) :4.
  • 3Jauhiainen K,Rintala E,Alfthan O,et al.Immunotherapy (BCG)versus chemotherapy (MMC) in intravesical treatment of superficial urinary bladder cancer.In:deKernion JB (Ed):Immunotherapy of Urological Tumors.New York:Churchill Livingstone,1990.13-26.
  • 4Lee ES,Kim HH,Min KJ,et al.A comparison of mitomycin C and bacillus Calmette-Guerin for the prophylaxis of high-risk superficial bladder tumors.Korean J Urol,1992,33:1014.
  • 5Lamn DL,Blumenstein BA,Crawford ED,et al.Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder.Urol Oncol,1995,1:119-126.
  • 6Vegt PD,Witjes JA,Witjes WP,et al.A randomized study of intravesical mitomycin C,bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder.J Urol,1995,153 (3 Pt 2):929-933.
  • 7Krege S,Giani G,Meyer R,et al.A randomized multicenter trial of adjuvant therapy in superficial bladder cancer:transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin.J Urol,1996,156:962-966.
  • 8Ayed M,Ben Hassine L,Ben Slama R,et al.Results of BCG in the treatment of pTa and pT1 bladder tumors.Evaluation of a long protocol using 75 mg of Pasteur strain BCG.Prog Urol,1998,8:206-210.
  • 9Witjes JA,v d Meijden AP,Collette L,et al.Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer.Urology,1998,52:403-410.
  • 10Malmstrom PU,Wijkstrom H,Lundholm C,et al.5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma.J Urol,1999,161:1124-1127.

共引文献35

同被引文献14

  • 1刘德育,罗曼.血清药理学方法研究蛇葡萄素抗B16黑色素瘤的作用[J].中药材,2001,24(5):348-350. 被引量:17
  • 2王行,王惠民.实时定量PCR技术的方法学分类[J].临床检验杂志,2007,25(1):71-72. 被引量:15
  • 3Steinberg G D, Brendler C B, Squire R A, et al. Experimental intravesical therapy for superficial transitional cell carcinoma in a rat bladder tumor model [J]. J Urol, 1991,145(3) :647-653.
  • 4Ojea A, Nogeira J L, Solsona E, et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette- Guerin ( 13.5 mg) versus mitomycin C [ J ]. Eur Urol, 2007,52 (5) : 1398-1406.
  • 5Bohle A, Brandau S. Immune mechanisms in bacillus Calmette- Guerin immunotherapy for superficial bladder cancer [J]. J Urol, 2003,170(3) :964-969.
  • 6Yang CC, Chu KC, Chen HY, et al. Expression of p16 and cyclin D1 in bladder cancer and correlation in cancer pro- gression[J]. Urol Int,2002,69(3) : 190.
  • 7秦红岩.高水溶性蛇葡萄素钠盐的制备及其抗肿瘤活性研究[D].兰州:兰州大学,2013.
  • 8萨姆布鲁克·J,拉塞尔·DW.分子克隆实验指南[M].黄培堂,译.3版.北京:科学出版社,2002:518.
  • 9王敏,潘晓婧,孟冰琦,吴勇杰.蛇葡萄素钠诱导人肝癌HepG2细胞凋亡和对CyclinD1表达的影响[J].中药药理与临床,2010,26(6):30-33. 被引量:4
  • 10徐明丽,韩伟,吴勇杰.蛇葡萄素钠协同卡铂抑制人肺腺癌SPC-A-1细胞增殖[J].中国临床药理学与治疗学,2011,16(8):890-894. 被引量:4

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部